China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
Asian Stocks Rally as Japan’s Nikkei Hits Record High on U.S.-Iran Peace Optimism 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
